POLE and neoplasm: The NCCN Clinical Practice Guidelines: Uterine Neoplasms (version 1, 2023) (9) and related studies have proven that POLE-mutated ECs harbored a high tumor mutational burden (TMB), infrequent recurrence, and a favorable prognosis.